已收录 268921 条政策
 政策提纲
  • 暂无提纲
Long-Term Skin Allograft Survival Elicited by a Finite Treatment with Antilymphocyte Serum Combined with Cytarabine
[摘要] Treatment with a pyrimidine nucleoside, cytarabine, combined with ALS, resulted in greatly prolonged survival of histoincompatible rat skin allografts in comparison with ALS or cytarabine used alone. Depending upon the potency of the ALS, 20% to 65% of the rats tolerated grafts for greater than 100 days despite the fact that treatment was limited to daily nontoxic doses of ALS and cytarabine given for only 10 and 22 days, respectively. With the same finite treatment, significant improvement of graft survival as compared with ALS given alone was achieved in sensitized animals, and in mouse-to-rat skin xenografts (31-day median survival). In the latter two cases, however, no animal permanently retained its graft. The possible mechanisms of the synergism of these two agents were discussed, and it was tentatively concluded that either concomitant suppression of both humoral and cellular responses or total suppression of the cellular response was responsible. Preliminary examination of the grafted animals indicated that graft survival was not due to specific immunologic tolerance to donor antigens and probably not to enhancement. It was tentatively concluded that “adaptation” of the grafts had occurred.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 生物科学(综合)
[关键词]  [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文